203663-26-7

Basic information

• Product Name: N-Boc-4-(hydroxyMethyl)-1,2,3,6-tetrahydropyridine
• Synonyms: N-Boc-4-(hydroxyMethyl)-1,2,3,6-tetrahydropyridine;tert-butyl 5,6-dihydro-4-(hydroxymethyl)pyridine-1(2H)-carboxylate;4-Hydroxymethyl-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester;tert-Butyl 4-(hydroxymethyl)-3,6-dihydropyridine-1(2H)-carboxylate
• CAS NO: 203663-26-7
• Molecular Formula: C₁₁H₁₉NO₃
• Molecular Weight: 213.27346
• Mol File: 203663-26-7.mol

Chemical Properties

• Boiling Point: 317.3±35.0 °C(Predicted)
• Appearance: /
• Density: 1.096±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 14.79±0.10(Predicted)
• CAS DataBase Reference: N-Boc-4-(hydroxyMethyl)-1,2,3,6-tetrahydropyridine(CAS DataBase Reference)
• NIST Chemistry Reference: N-Boc-4-(hydroxyMethyl)-1,2,3,6-tetrahydropyridine(203663-26-7)
• EPA Substance Registry System: N-Boc-4-(hydroxyMethyl)-1,2,3,6-tetrahydropyridine(203663-26-7)

Safety Data

• Hazardous Substances Data: 203663-26-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
N-Boc-4-(hydroxyMethyl)-1,2,3,6-tetrahydropyridine is used as a synthetic reagent for the production of 5-acyl-4-methylene-1,2,3,4-tetrahydropyridines, which are important building blocks in the development of pharmaceutical compounds with potential therapeutic applications.
Used in Organic Chemistry Research:
In the field of organic chemistry, N-Boc-4-(hydroxyMethyl)-1,2,3,6-tetrahydropyridine is utilized as a key intermediate for the synthesis of complex organic molecules, contributing to the advancement of chemical research and the discovery of new chemical entities with potential applications in various industries.

Upstream product

• 159635-49-1 tert-butyl 4-methylidenepiperidine-1-carboxylate 
• 184368-74-9 3,6-dihydro-2H-pyridine-1,4-dicarboxylic acid 1-tert-butyl ester 4-methyl ester 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 138647-49-1 4-Trifluoromethanesulfonyloxy-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 
• 71233-28-8 3-hydroxypiperidine-1,4-dicarboxylic acid 1-tert-butyl ester 4-ethyl ester 
• 906663-30-7 3,6-dihydro-2H-pyridine-1,4-dicarboxylic acid 1-tert-butyl ester 4-ethyl ester 
• 147804-30-6 1-oxa-6-aza-spiro-[2.5]octane-6-caboxylic acid tert-butyl ester 
• 138022-91-0 tert-butyl 4-(methoxymethylene)piperidine-1-carboxylate 
• 941571-79-5 ethyl 3-hydroxypiperidine-4-carboxylate 
• 52763-21-0 ethyl 1-benzyl-3-oxopiperidine-4-carboxylate hydrochloride 

Downstream Products

• 181271-48-7 4-[(2-Bromo-phenylamino)-methyl]-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 
• 181271-47-6 4-(2-Bromo-phenoxymethyl)-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 
• 159635-24-2 4-(2-bromo-phenylsulfanylmethyl)-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 
• 181271-49-8 4-{[Acetyl-(2-bromo-phenyl)-amino]-methyl}-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 
• 1419006-62-4 4-{[(4-chloro-2-iodo-phenyl)-(2,2,2-trifluoro-acetyl)-amino]-methyl}-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 
• 203663-27-8 [3-(tert-Butoxycarbonyl)-3-azabicyclo[4.1.0]hept-6-yl]methanol 
• 1345728-54-2 tert-butyl 6-[(benzyloxy)methyl]-7-oxa-3-azabicyclo[4.1.0]heptane-3-carboxylate 
• 1345728-48-4 tert-butyl 4-[(benzyloxy)methyl]-4-hydroxypiperidine-1-carboxylate 
• 1345728-55-3 tert-butyl 4-[(benzyloxy)methyl]-4-methoxypiperidine-1-carboxylate 
• 239073-94-0 tert-butyl 4-(hydroxymethyl)-4-methoxypiperidine-1-carboxylate 
• 1345728-59-7 tert-butyl 6-[(benzyloxy)methyl]-3-azabicyclo[4.1.0]heptane-3-carboxylate 
• 1345728-47-3 tert-butyl 4-[(benzyloxy)methyl]-3,6-dihydropyridine-1(2H)-carboxylate 
• 1345728-65-5 tert-butyl 4-[(benzyloxy)methyl]-3-fluoro-4-hydroxypiperidine-1-carboxylate 
• 219975-81-2 1,1-dimethylethyl trans-3-hydroxy-4-(hydroxymethyl)-1-piperidinecarboxylate 

Relevant articles and documents

Synthesis of 5-Acyl-4-methylene-1,2,3,4-Tetrahydropyridines

Several approaches to monocyclic N-protected 4-methylene-1,2,3,4-Tetrahydropyridines are reported. N-Boc-4-methylenepiperidin-3-one was found to be unstable and its enol triflate was not easily accessible. However, N-protected 2,3-dihydropyridin-4-ones ar

Design, Synthesis, and Monoamine Oxidase Inhibitory Activity of (+)-Cinchonaminone and Its Simplified Derivatives

The absolute structure of an indole alkaloid (+)-cinchonaminone by total synthesis of both (+)-cinchonaminone and its enantiomer was determined. The main focus of the study was the enantioselective synthesis of both enantiomers of a chiral cis-3,4-disubstituted piperidine. We also evaluated monoamine oxidase (MAO) inhibitory activities of these enantiomers. Furthermore, its structurally simplified derivatives were synthesized that did not have any chiral center. Two of these derivatives showed stronger MAO inhibitory activities than that of (+)-cinchonaminone.

C10-ALKYLENE SUBSTITUTED 13-MEMBERED MACROLIDES AND USES THEREOF

Provided are 13-membered macrolides for the treatment of infectious diseases. The 13-membered macrolides described herein are azaketolides. Also provided are methods for preparing the 13- membered macrolides, pharmaceutical compositions comprising the 13-membered macrolides, and methods of treating infectious diseases, and in particular, disease resulting from Gram negative bacteria using the disclosed macrolides. Formula (I)

PYRAN DERVATIVES AS CYP11A1 (CYTOCHROME P450 MONOOXYGENASE 11A1) INHIBITORS

Compounds of formula (I) wherein R1, R2,R3,R4,R5,R23,R24,L, A and Bare as defined in claim 1, or pharmaceutically acceptable salts thereof are disclosed. The compounds of formula (I) possess utility as cytochrome P450 monooxygenase 11A1(CYP11A1) inhibitors. The compounds are useful as medicaments in the treatment of steroidreceptor, particularly androgen receptor,dependent diseases and conditions, such asprostate cancer.

Conformationally constrained ortho- Anilino diaryl ureas: Discovery of 1-(2-(1′-Neopentylspiro[indoline-3,4′-piperidine]-1-yl)phenyl) -3-(4-(trifluoromethoxy)phenyl)urea, a potent, selective, and bioavailable P2Y1 antagonist

Preclinical antithrombotic efficacy and bleeding models have demonstrated that P2Y1 antagonists are efficacious as antiplatelet agents and may offer a safety advantage over P2Y12 antagonists in terms of reduced bleeding liabilities. In this article, we describe the structural modification of the tert-butyl phenoxy portion of lead compound 1 and the subsequent discovery of a novel series of conformationally constrained ortho-anilino diaryl ureas. In particular, spiropiperidine indoline-substituted diaryl ureas are described as potent, orally bioavailable small-molecule P2Y1 antagonists with improved activity in functional assays and improved oral bioavailability in rats. Homology modeling and rat PK/PD studies on benchmark compound 3l will also be presented. Compound 3l was our first P2Y1 antagonist to demonstrate a robust oral antithrombotic effect with mild bleeding liability in the rat thrombosis and hemostasis models.

Benzopiperidine derivatives

Benzopiperidine derivatives represented by formula (I), salts thereof or hydrates thereof, processes for producing the same and drugs comprising the same: wherein the variables are as described in the specification. These compounds are useful as drugs efficacious in the prevention and treatment of these various inflammatory diseases and immunologic diseases, such as rheumatoid arthritis, atopic dermatitis, psoriasis, asthma, and rejection reaction accompanying organ transplantation.

Free radical method for the synthesis of spiro-piperidinyl heterocycles

A general approach to spiro-piperidinyl heterocycles (1, X = S, O, NH, NAc) was obtained from the key intermediate 3 via an efficient radical reaction.